Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. 詳細を表示
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1951 | 33.6437316779 | 0.5799 | 0.89 | 0.56 | 38056 | 0.62271597 | CS |
4 | 0.115 | 17.4242424242 | 0.66 | 1.09 | 0.5209 | 238110 | 0.74702076 | CS |
12 | 0.192599 | 33.0698264598 | 0.582401 | 1.1099 | 0.49 | 328845 | 0.83292261 | CS |
26 | -0.895 | -53.5928143713 | 1.67 | 1.68 | 0.49 | 159656 | 0.83404004 | CS |
52 | -0.025 | -3.125 | 0.8 | 1.87 | 0.49 | 86237 | 0.86689438 | CS |
156 | -6.305 | -89.0536723164 | 7.08 | 7.6 | 0.49 | 55799 | 2.37322613 | CS |
260 | -14.185 | -94.8195187166 | 14.96 | 19.56 | 0.49 | 341776 | 10.66160582 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約